QGEN · NYSE · STOCK
Qiagen (QGEN) Stock Analysis
$45.40
52W $32.53 – $57.82
62/100
$9.36B
23.3
0.61
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is QGEN Bullish or Bearish?
Bullish.
Innellis AI committee rates Qiagen N.V. (QGEN) Buy with a composite score of 62/100
, based on 5 analysts with 80% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.27 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.73 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Supporting evidence favours the bullish case. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
62/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 22%
of 192 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst
bullish
62
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
59
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
61
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 61.7 to 61.7.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
58.2
Neutral
MACD Histogram
0.080
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$43.76
Resistance
$45.52
Bollinger %B
0.79
Inside Bands
Price vs Moving Averages
EMA 9
$44.74
Above
EMA 21
$44.22
Above
EMA 50
$43.23
Above
EMA 200
$42.39
Above
Fundamental Analysis
Valuation
71
Growth
60
Profitability
80
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
23.3×
P/B Ratio
2.79×
PEG Ratio
1.66
Dividend Yield
5.82%
52W High
$57.82
52W Low
$32.53
Quality & Growth
ROE
1124.6%
ROA
674.9%
Gross Margin
6182.4%
Operating Margin
2533.3%
Revenue Growth YoY
—
Debt / Equity
0.49
AI Fundamental Assessment
P/E ratio of 23.3 (inexpensive relative to a 15-40x range); Price-to-book of 2.8x; PEG ratio of 1.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.2%; Return on assets of 6.7%; Net margin of 19.5%; Gross margin of 61.8%; Current ratio of 2.85 (healthy short-term liquidity); Debt-to-equity of 0.49; Free cash flow per share is positive (2.17); Most recent quarter beat estimates by 1.6%; EPS growth accelerating (-12.9% -> +14.8% QoQ); Analyst estimates falling over recent quarters
Get the Full QGEN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →